All In Biotech

NDA 020649 · Endo Operations

Edex

Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist

Last checked: Nov 19, 2026Latest source record: Nov 17, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jun 12, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

145

40 Phase 3, 8 recruiting

FAERS reports

1,989

1,604 serious, 241 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 27, 2024.

INDICATIONS AND USAGE edex ® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Mechanism: Mode of Action Alprostadil is a smooth muscle relaxant. Precontracted isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery are relaxed by alprostadil. Alprostadil has been shown to bind to specific receptors in human penile tissue. Two types of receptors that differ in their PGE 1 binding affinity have been identified. The binding of alprostadil to its receptors is accompanied by an increase in intracellular cAMP levels. Human cavernous smooth muscle cells respond to alprostadil by releasing intracellular calcium into the surrounding medium. Smooth...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 12, 1997 Original approval · Type 3 - New Dosage Form Review
7 products under this application
  • EDEX · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription
  • EDEX · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • EDEX · ALPROSTADIL 0.005MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • EDEX · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription
  • EDEX · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • EDEX · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • EDEX · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.

All 145 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective257
  • off label use128
  • haemoglobin decreased82
  • lymphocyte count decreased79
  • diarrhoea73
  • pyrexia72
  • cardiac failure70
  • priapism62
  • blood urea increased59
  • condition aggravated57
  • anaemia56
  • blood glucose increased56

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200449
200566
200679
200742
200857
200931
201063
2011113
201276
201338
201424
2015119
2016144
2017184
2018114
2019138
2020108
2021114
202286
202380
2024102
202587
202674

Recalls

1 FDA enforcement reports for this application.

  • Feb 22, 2017 · Class II · Terminated

    Lack of Assurance of Sterility: Defective container resulting in the lack of sterility assurance. ok thanks

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 199 on PubMed

Sponsor: Endo Operations

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.